ľֱ

Thyroid Drug & Bone Loss; GLP-1s' Renal Benefit; Menopause Musculoskeletal Syndrome

— News and commentary from the endocrinology world

by Kristen Monaco, Senior Staff Writer, ľֱ

MedpageToday
Endo Break over a computer rendering of a man with illustrated body organs.

The thyroid medication levothyroxine , according to a study that will be presented at the Radiological Society of North America's annual meeting.

In a phase II study, (MariTide) yielded around 20% weight loss at 52 weeks, Amgen announced.

A meta-analysis of 11 randomized trials in type 2 diabetes showed that GLP-1 receptor agonists significantly , kidney failure, and cardiovascular events. (Lancet Diabetes & Endocrinology)

The the presence and impact of per- and polyfluoroalkyl substances -- endocrine-disruptors known as forever chemicals -- in the nation's seafood.

Treatment with the aromatase inhibitor anastrozole and improved height outcomes in children with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. (Journal of Clinical Endocrinology & Metabolism)

Body aches with menopause? It could be the . (New York Times)

Disparities in access to could be made worse if the medications are denied to people who cannot participate in comprehensive lifestyle intervention programs due to competing demands or comorbidities, editors at JAMA Internal Medicine argued.

The food industry is grappling with a possible with the increased use of GLP-1 receptor agonists like semaglutide (Wegovy, Ozempic). (New York Times Magazine)

Metabolic syndrome was associated with in a 25-year cohort study. (Lancet Healthy Longevity)

The glucagon analog dasiglucagon (Zegalogue) needed to maintain euglycemia in a small placebo-controlled trial of infants with congenital hyperinsulinism. (Journal of Clinical Endocrinology & Metabolism)

CVS Health, UnitedHealth Group, and Cigna , claiming the agency's case against their pharmacy benefit managers over high insulin prices is unconstitutional. (CNBC)

Is Eli Lilly's investigational weight-loss treatment ? The distinction could hold significant implications for compounding capabilities. (Endpoints News)

Compared with placebo, initiated in early postmenopause was not associated with long-term cognitive effects, according to the KEEPS-Cog trial. (PLOS Medicine)

Should people without diabetes ? (USA Today)

  • author['full_name']

    Kristen Monaco is a senior staff writer, focusing on endocrinology, psychiatry, and nephrology news. Based out of the New York City office, she’s worked at the company since 2015.